Anavex Life Sciences Corp.
AVXL· Nasdaq
AVXLAnavex Life Sciences Corp.
Filed May 13, 2025 · 10-Q · 43 days after period end · 0001731122-25-000724
| Metric | Q2 2025 | Q2 2024 | Q2 2023 | Q2 2022 |
|---|---|---|---|---|
| Net Income | -$11.20M | -$10.55M | -$13.11M | -$10.44M |
| EPS Diluted | -$0.13 | -$0.13 | -$0.17 | — |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Anavex Life Sciences Corp. · CIK 1314052 · Engraved from SEC EDGAR
ended Mar 31, 2025 · filed May 13, 2025 · 43 d after period end
